Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator | Zendy

Ilan Goldenberg | Zendy; John A. Gillespie | Zendy; Arthur J. Moss | Zendy; William J. Hall | Zendy; Helmut Klein | Zendy; Scott McNitt | Zendy; Mary W. Brown | Zendy; Iwona Cygankiewicz | Zendy; Wojciech Zaręba | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator

Author(s) -

Ilan Goldenberg,

John A. Gillespie,

Arthur J. Moss,

William J. Hall,

Helmut Klein,

Scott McNitt,

Mary W. Brown,

Iwona Cygankiewicz,

Wojciech Zaręba

Publication year - 2010

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.110.940148

Subject(s) - medicine , hazard ratio , implantable cardioverter defibrillator , confidence interval , proportional hazards model , cardiology

The Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) showed a significant 31 reduction in the risk of death with primary implantable cardioverter-defibrillator (ICD) therapy during a median follow-up of 1.5 years. However, currently there are no data on the long-term efficacy of primary defibrillator therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research